Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — Wells Fargo Healthcare Conference 2023
15 slides from Amneal Pharmaceuticals's conference presentation, Sep 7, 2023
Slide 1: Amneal Pharmaceuticals
Amneal Pharmaceuticals Chirag Patel, Co-founder & Co-CEO Wells Fargo Healthcare Conference g September 7, 2023
Slide 2: Cautionary Statement on Forward Looking Statements
Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements reg
Slide 3: Key healthcare macro trends and how Amneal is well aligned
Key healthcare macro trends and how Amneal is well aligned Global aging population Need for affordable medicines Need for consistent supply Industry-leading R&D & manufacturing Expansive portfolio of ~270 medicines capabilities to provide products from Track record of high quality and across Retail
Slide 4: Amneal Pharmaceuticals – We make healthy possible
Amneal Pharmaceuticals – We make healthy possible® • Global diversified pharmaceutical company with a growing portfolio of ~270 products across Retail Generics, Injectables, Biosimilars and Specialty, and an expanding AvKARE distribution business • Highly productive R&D engine focused on complex and
Slide 5: Affordable medicines generating sustainable, profitable growth
GENERICS Affordable medicines generating sustainable, profitable growth Regularly refreshing & diversifying Generics portfolio ~67 pipeline programs with ~$32B TAM (1) Innovative R&D pipeline drives 20-30 new launches per year RETAIL GENERICS INJECTABLES ~92 • #4 U.S. Generics business • ~30 institu
Slide 6: Transforming our specialty business with expanding portfolio
SPECIALTY Transforming our specialty business with expanding portfolio Build on strength in key brands Potential Launch Program Therapeutic Area Specialty highlights to achieve $500M+ sales by 2027 2024* IPX203 Parkinson’s ($ millions) $500+ Migraine and Cluster Q1 2025 DHE Autoinjector Therapeutic
Slide 7: Delivering double-digit growth in AvKARE business
AvKARE Delivering double-digit growth in AvKARE business Expect 19%+ CAGR from 2020 to 2023 ($ millions) ~$500 AvKARE strategic focus areas $406 $349 • Operates as a contract administrator (wholesaler and re-packager selling to hospitals and U.S. $294 Government agencies) with 3 business units: – Go
Slide 8: Continued track record of driving top and bottom-line growth
Continued track record of driving top and bottom-line growth (1) Net Revenue Growth Adjusted EBITDA Growth ($ millions) Mid-to-high single ($ millions) digit growth $2,300 - $2,400 +22% +6% $2,212 $525 - $540 $2,094 High-single +5% $514 +4% $1,993 $374 digit growth $512 organic $378 ~$500 $356 $1,62
Slide 9: Global diversified pharmaceuticals company with a clear strategy for sustainable growth
Global diversified pharmaceuticals company with a clear strategy for sustainable growth 2022 Business area Strategy for growth Growth projection(1) Net Revenue Retail Grow #4 U.S. Generics portfolio of ~230 products with new Low-single digit growth Generics launches and shift to complex dosage forms
Slide 10: Well-positioned to expand reach and impact on patients around the world
Well-positioned to expand reach and impact on patients around the world Diversified and growing portfolio of essential medicines with multiple paths to accelerated growth across business Expansive global capabilities across R&D, manufacturing and commercial to drive growth at scale Robust R&D engine
Slide 11: Appendix
amneal We make healthy possible Appendix
Slide 12: Differentiated R&D and manufacturing capabilities
Differentiated R&D and manufacturing capabilities Best-in-class R&D and manufacturing capabilities Global network of FDA-approved, delivering complex & high-value dosage forms cGMP manufacturing sites INJECTABLES TRANSDERMALS ORAL SOLIDS, & STERILE LIQUIDS & TOPICALS Matrix Peptides Hydrogel IR/ER t
Slide 13: Significant growth catalysts across portfolio
Significant growth catalysts across portfolio Retail Generics Injectables Biosimilars Specialty International Recently Year-to-date launches Year-to-date Launches Launched IPX203 pending NDA Launched completed ✓ Posaconazole, Pirfenidone, ✓ Azacitidine, Prochlorperazine ✓ ALYMSYS®, a • Early October
Slide 14: Entering key global markets with impactful pharmaceuticals
INTERNATIONAL EXPANSION Entering key global markets with impactful pharmaceuticals Geography Direct / Partner Strategy and status India Direct • Utilizing commercial team to launch Expanding local products locally presence • Focusing on the hospital, ophthalmics, and specialty products markets Europ
Slide 15: Reconciliation of net (loss) income to EBITDA and adjusted EBITDA
Reconciliation of net (loss) income to EBITDA and adjusted EBITDA Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. 15
Amneal Pharmaceuticals — Wells Fargo Healthcare Conference 2023 on 6ix